| Document |
Document Title |
|
WO/2023/172415A1 |
Described herein are compounds useful as sweet flavor modifiers. Ingestible compositions that include one or more of these compounds in combination with a natural or artificial sweetener are also described. (I)
|
|
WO/2023/165943A1 |
The invention relates to novel compounds having the general formula (I), wherein R1, R10, Rx, Ry, Y, m, and n are as described herein, composition including the compounds and methods of using the compounds.
|
|
WO/2023/156386A2 |
A compound comprising the following formula: wherein R1 is selected from H and a substituted or unsubstituted organic group; R2 may be present or absent and is independently selected from H and a substituted or unsubstituted organic grou...
|
|
WO/2023/154302A1 |
The invention provides macromolecule-supported compounds of Formula I comprising a macromolecule linked by conjugation to one or more 8-sulfonyl-2-aminobenzazepine derivatives. The invention also provides 8-sulfonyl-2-aminobenzazepine de...
|
|
WO/2023/154307A1 |
The invention provides immunoconjugates of Formula. (I) comprising an antibody linked by conjugation to one or more 8-sulfonyl-2-aminobenzazepine derivatives. The invention also provides 8-sulfonyl-2-aminobenzazepine derivative intermedi...
|
|
WO/2023/145804A1 |
The purpose of the present invention is to provide a novel B0AT1 inhibitor. The present invention relates to a compound represented by formula (I): (the symbols in the formula are as described in the description) or a salt thereof. The p...
|
|
WO/2023/143386A1 |
The present invention relates to an aromatic ring-fused heterocyclic ring compound as a potassium channel regulator, and the preparation therefor and the use thereof. Specifically, the compound of the present invention has a structure as...
|
|
WO/2023/144337A1 |
The present invention provides an improved process for the recovery of ε-caprolactam from Nylon 6 comprising multi-component material, in particular multi-layered film. Further, the invention provides a plant configured to carry out the...
|
|
WO/2023/144338A1 |
The present invention provides a process and a plant for recovering purified ε-caprolactam from polyamide 6 comprising fishing nets, wherein the plant comprises a depolymerization section [B], a recovery section [C], and a purification ...
|
|
WO/2023/118968A2 |
Disclosed herein are methods of detecting xanthine oxidase expression in polycystic kidney disease, or methods of delaying the onset or treating polycystic kidney disease, or both. The inventors have made the remarkable discovery that ab...
|
|
WO/2023/094828A1 |
Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: (I) wherein Ring A, R1, R2, R3, R4, Y1, Y2, Y3, Y4, a, t, u, and L are as defined herein. The compounds are antagonists of the resistant (R-type) v...
|
|
WO/2023/088420A1 |
The present disclose includes, among other things, compounds that treat or lessen the severity of cancer, pharmaceutical compositions and methods of making and using the same.
|
|
WO/2023/084441A1 |
The present invention relates to a process for producing ε-caprolactam by depolymerization of polycaprolactam (PA6) which comprises : a. contacting a composite material comprising PA6 and at least one fibrous reinforcing material with a...
|
|
WO/2023/074432A1 |
Provided is a green, energy-saving production method that achieves both re-utilization of a fossil resource and reduction of greenhouse gas emissions in a method for producing ε-caprolactam from a polyamide 6 resin composition. The pres...
|
|
WO/2023/072199A1 |
The present invention relates to the field of caprolactam production. Disclosed is a method for producing high-purity ε-caprolactam. The method comprises the following steps: (1) carrying out a gas-phase Beckmann rearrangement reaction ...
|
|
WO/2023/074441A1 |
Provided is a green, energy-conserving method for producing ε-caprolactam from a polyamide 6 resin composition, wherein said method achieves both fossil resource recycling and a reduction in greenhouse gas emissions. The present inventi...
|
|
WO/2023/074437A1 |
The present invention provides a recovery method with less energy consumption, the recovery method being capable of recovering ε-caprolactam and a polyamide 6 oligomer with high yield by depolymerization with use of a little water and s...
|
|
WO/2023/064164A1 |
The present invention is generally directed to dual inhibitors of poly (ADP-ribose) polymerase (PARP) and Wee1 useful in the treatment of diseases and disorders modulated by said enzymes and having the Formula (A): P-L-W (A), wherein P i...
|
|
WO/2023/040998A1 |
Provided herein are a series of compounds as potent inhibitors of cyclin-dependent kinase (CDK), or pharmaceutically acceptable salts thereof. Corresponding compositions are also provided.
|
|
WO/2023/025276A1 |
Disclosed in the present invention is a compound having a structure shown in general formula I, or a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a solvate thereof. Further disclosed in the present invention are a...
|
|
WO/2023/285788A1 |
A process for preparing a compound of formula (I), or a salt thereof, as defined herein. Also, compounds of formula I and intermediate compounds useful in the preparation of a compound of formula (I).
|
|
WO/2022/266363A1 |
Provided herein are compounds of Formula (I), their pharmaceutically acceptable salts, and their pharmaceutical compositions: wherein R1, R2, R3a, R3b, R4, R5, and A are defined in the present disclosure. The compounds are potent inhibit...
|
|
WO/2022/265960A1 |
A method of preventing or treating neuronal damage in a patient being administered a therapy that can cause nerve damage, comprising administering to said patient an effective amount of a neuroprotective compounds for Formula 1, (I) wher...
|
|
WO/2022/261524A1 |
The present disclosure provides phosphonate-containing heterocycle compounds with TYK2 kinase inhibitory activity, pharmaceutical compositions comprising the same, and applications thereof. The present disclosure provides compounds of Fo...
|
|
WO/2022/250108A1 |
The present invention pertains to a therapeutic agent or preventative agent against diseases involving an orexin receptor, particularly an orexin type-2 receptor, the agent containing a novel compound having a urea skeleton, or a pharmac...
|
|
WO/2022/242724A1 |
The present application relates to a nitrogen-containing compound, a conjugate containing said compound, and an application thereof. Specifically, the present application provides a compound represented by formula (I), a solvate thereof,...
|
|
WO/2022/243097A1 |
A process to produce N-vinyl compounds by homogeneous catalysis, wherein acetylene is re-acted with a compound having at least one nitrogen bearing a substitutable hydrogen residue in a liquid phase in the presence of at least one phosph...
|
|
WO/2022/228413A1 |
Disclosed in the present invention are an RIPK1 inhibitor for inhibiting programmed cell death and a preparation method therefor. The RIPK1 inhibitor of the present invention is as represented by general formula I, wherein X, Y, Z, L, R1...
|
|
WO/2022/207938A1 |
A novel class of ionizable lipid compounds as well as lipid nanoparticles comprising said ionizable lipid compounds is provided. Advantageously, upon hydrolysis of an internal ester bond, which is likely to occur under typical in vivo co...
|
|
WO/2022/211631A1 |
A continuous method for depolymerizing polycaprolactam waste into caprolactam is described. In the method, a melt of the polycaprolactam waste and an inert gas are fed to a reactor in a continuous manner. Water and an aromatic hydrocarbo...
|
|
WO/2021/257696A9 |
Compounds and methods are provided for inhibiting an aldehyde dehydrogenase (ALDH). Methods of treating cancer are also provided. The ALDH-inhibitor can be a compound that is based on a cyclic guanidine, or an imidazolium core. In certai...
|
|
WO/2022/196043A1 |
The present invention further improves the selectivity of ε-caprolactam. This method is for producing zeolite and comprises steps (1)-(5). Step (1): A step for mixing tetraalkyl orthosilicate, water, and a hydroxylated quaternary am...
|
|
WO/2022/189911A1 |
Method for the preparation of amidines or their derivatives, comprising the following steps: - synthesis of nitrile lactams by reaction between a lactam and an α-β unsaturated nitrile; - synthesis of N-(aminoalkyl) lactams by reducing ...
|
|
WO/2022/185227A1 |
The present invention relates to novel Formyl Peptide Receptor subtype 2 (FPR2) agonist compounds and their use in the recovery of the inflammatory phenomena in which said receptor is involved, particularly in the context of the treatmen...
|
|
WO/2022/184172A1 |
A benzazepine fused ring derivative as represented by formula (I) or a pharmaceutically acceptable salt thereof, and the use of a compound in the diagnosis, prevention and/or treatment of diseases related to vasopressin receptors.
|
|
WO/2022/168884A1 |
The present invention provides a novel cationic lipid having excellent encapsulation and delivery stability of nucleic acid medicines. Provided is a compound represented by formula (I) or a pharmacologically acceptable salt thereof. (In ...
|
|
WO/2022/162471A1 |
Disclosed are compounds, compositions, and methods useful for treating neuronal and mitochondrial diseases.
|
|
WO/2022/156449A1 |
The present invention relates to a novel benzoazepine compound, comprising a pharmaceutically acceptable salt thereof. The present invention also provides a pharmaceutical composition comprising the compound and pharmaceutically acceptab...
|
|
WO/2022/152097A1 |
The present disclose includes, among other things, compounds that treat or lessen the severity of cancer, pharmaceutical compositions and methods of making and using the same.
|
|
WO/2022/155037A1 |
Disclosed are compounds for treating or preventing a disease or disorder responsive to antagonism of a P2Y14R receptor agonist in a mammal in need thereof, for example, compounds of formulas (I) and (II), wherein R1‑R8, X, Y, Z, X', Y'...
|
|
WO/2022/111581A1 |
A benzazepine spiro derivative as represented by formula (I) and a pharmaceutically acceptable salt thereof, and the use of a compound in the diagnosis, prevention and/or treatment of diseases related to vasopressin receptors.
|
|
WO/2022/090138A1 |
The present invention relates to new processes for the preparation of known polymorphs of ivabradine HCl, said processes being characterized by robust protocols suitable for industrial production.
|
|
WO/2022/060811A1 |
In one aspect, use of compounds as active agents to treat a hearing impairment and to prevent a hearing impairment, and methods of treating and/or preventing hearing impairments or disorders using the compositions are disclosed. (E)-1-(3...
|
|
WO/2022/036080A1 |
The present disclosure relates to compounds of Formula (I) and their prodrugs, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods of their preparation. The compounds disclosed herein are...
|
|
WO/2022/022612A1 |
The invention relates to novel glutamine analogs shown as the formula I, a composition containing the glutamine analogs and the use thereof.
|
|
WO/2022/025117A1 |
The present invention provides the compound represented in general formula (A1) [Ar1 is a C6-14 aryl group or a C5-14 nitrogen-containing heteroaryl group, substituted with at least two electron-attracting groups; R1 is a C1-30 alkyl gro...
|
|
WO/2022/014397A1 |
This refining method is for crystallizing a compound having at least one crystal form. A specific infrared wavelength and a specific concentration at which a specific crystal form precipitates from a solution in which the compound is dis...
|
|
WO/2022/014396A1 |
A purification method according to the present invention is a purification method that brings about the crystallization of a compound that has at least one crystalline form. A prescribed infrared wavelength and prescribed temperature at ...
|
|
WO/2021/249877A1 |
The present invention relates to new intermediates for the synthesis of Tolvaptan and of its derivatives and a process for its preparation involving said intermediates.
|
|
WO/2021/226440A1 |
The invention provides immunoconjugates of Formula I comprising a cell-binding agent linked by conjugation to one or more immunostimulatory moieties where the linker is a substrate for elastase. The invention also provides immunostimulan...
|
